| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.080 | Biomarker | disease | BEFREE | Our data also suggest that brain and kidney cancer have patterns of transcriptomic dysregulation in the PI3K/AKT/MTOR axis that are similar to those found in ASD. | 31007884 | 2019 | ||||
|
0.080 | Biomarker | disease | BEFREE | The mammalian target of rapamycin (mTOR) inhibitor everolimus is used in the treatment of breast cancer, neuroendocrine tumors, and renal cancer. | 28762135 | 2018 | ||||
|
0.080 | AlteredExpression | disease | BEFREE | This may exploit tumor-specific characteristics, such as targeting Vascular Endothelial Growth Factor (VEGF) signaling and mammalian Target of Rapamycin (mTOR) activity in renal cancer and inducing survival factor deprivation by targeting androgen signaling in prostate cancer. | 29371637 | 2018 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | Using publicly available tumor genome sequencing data, we identified several point mutations in MTOR and its upstream regulator RHEB (Ras homolog enriched in brain) in patients with clear cell renal cell carcinoma (ccRCC), the most common histology of kidney cancer. | 26255626 | 2015 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | A functional variant in the MTOR promoter modulates its expression and is associated with renal cell cancer risk. | 23209702 | 2012 | ||||
|
0.080 | AlteredExpression | disease | BEFREE | Similar to other factors implicated in kidney cancer, FLCN has been shown to modulate activation of mammalian target of rapamycin (mTOR). | 22709692 | 2012 | ||||
|
0.080 | AlteredExpression | disease | BEFREE | Together, the phosphorylation of PRAS40 is critical for the activation of mTOR in CNI-induced VEGF overexpression and renal cancer progression. | 21886838 | 2011 | ||||
|
0.080 | Biomarker | disease | BEFREE | Ongoing clinical trials are evaluating renal cell cancer and other malignancies using therapy with mTOR inhibitors. | 14751088 | 2004 |